Li Raymond, Curtis Kate, Zaidi Syed Tabish Razi, Van Connie, Castelino Ronald
Faculty of Medicine and Health, University of Sydney , Camperdown, Australia.
Faculty of Medicine and Health, University of Leeds , Leeds, England.
Expert Opin Drug Saf. 2020 Jun;19(6):747-753. doi: 10.1080/14740338.2020.1746762. Epub 2020 Mar 31.
The black triangle scheme was introduced to Australia in January 2018 to improve the significant under-reporting of adverse drug events (ADEs). The authors investigated the impact of the black triangle scheme on the quantity and quality of ADE reports submitted to the Therapeutic Goods Administration.
An interrupted time series analysis with segmented regression was conducted to compare the quantity of ADE reports pre and post the black triangle intervention for the period between January 2017 and December 2018. The quality of reports was measured by the ability to apply the World Health Organization - Uppsala Monitoring Center algorithm to evaluate a causal relationship between the medicine and ADE.
A total of 384 ADE reports were extracted for the 33 medicines approved in 2017 and 135 ADE reports for the 36 black triangle medicines. Time series analysis showed that there was a monthly increase of 0.41 reports per medicine (95%CI, 0.02-0.80, p = 0.039) post the black triangle intervention. There was a higher proportion for high quality reports for black triangle medicines versus 2017 medicines (22.2% vs 7.6%, p < 0.001).
The black triangle scheme was marginally successful in improving ADE reporting and additional strategies are required to enhance the overall pharmacovigilance system in Australia.
“黑三角”计划于2018年1月引入澳大利亚,以改善不良药物事件(ADEs)报告严重不足的情况。作者调查了“黑三角”计划对提交给治疗用品管理局的ADE报告数量和质量的影响。
采用分段回归的中断时间序列分析,比较2017年1月至2018年12月期间“黑三角”干预前后ADE报告的数量。报告质量通过应用世界卫生组织-乌普萨拉监测中心算法评估药物与ADE之间因果关系的能力来衡量。
共提取了2017年批准的33种药物的384份ADE报告和36种“黑三角”药物的135份ADE报告。时间序列分析表明,“黑三角”干预后,每种药物每月报告增加0.41份(95%CI,0.02-0.80,p = 0.039)。与2017年的药物相比,“黑三角”药物高质量报告的比例更高(22.2%对7.6%,p < 0.001)。
“黑三角”计划在改善ADE报告方面取得了一定成功,需要额外的策略来加强澳大利亚的整体药物警戒系统。